Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsLTS:0RKT 66 Median PS Value is zł98.09 as of Jul. 16, 2026, which is 100% below its 10-year median of 1.34. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł86.63. The stock has 3 warning signs investors should review. Among 277 Biotechnology companies, Ryvu Therapeutics ranks better than 81.95% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Ryvu Therapeutics's Median PS Value or its related term are showing as below:
LTS:0RKT'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31 Med: 1.34 Max: 14.19
Current: 0.31
During the past 13 years, the highest Price to Median PS Value of Ryvu Therapeutics was 14.19. The lowest was 0.31. And the median was 1.34.
LTS:0RKT's Price-to-Median-PS-Value is ranked better than 81.95% of 277
companies
in the Biotechnology industry
Industry Median: 0.64
vs LTS:0RKT: 0.31
Ryvu Therapeutics (LTS:0RKT) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Ryvu Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
30.25
/
98.09
=
0.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics Median PS Value Related Terms
Ryvu Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKT vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 35.9436.
Ryvu Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł2.729.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics (LTS:0RKT) has a Median PS Value of zł98.09 as of Jul. 16, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Ryvu Therapeutics and its competitors. This is 7220% above median its historical median of 1.34. Over the past decade, Ryvu Therapeutics' Median PS Value has ranged from 0.31 to 14.19. According to the industry distribution chart, Ryvu Therapeutics ranks #50 out of 277 companies in the Biotechnology industry, placing it in the top 18.1%.
Is Ryvu Therapeutics' Median PS Value too high?
Ryvu Therapeutics' current Median PS Value of zł98.09 is 7220% above median its 10-year median of 1.34. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 14.19. Based on the distribution chart, Ryvu Therapeutics ranks #50 out of 277 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #50 out of 277 companies for Median PS Value. This places Ryvu Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.64. Historically, Ryvu Therapeutics' own Median PS Value has ranged from 0.31 to 14.19 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.64, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Median PS Value is zł98.09, which is 7220% above median its own 10-year median of 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Median PS Value of zł98.09. The stock's GF Value™ is zł86.63, compared to a current price of zł30.25 — trading 65.1% below its estimated fair value. The current Median PS Value is zł98.09, which is 7220% above median its 10-year median of 1.34. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Median PS Value is zł98.09 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł30.25 is trading 65.1% below its estimated GF Value™ of zł86.63.
Key valuation signals for LTS:0RKT:
Median PS Value: zł98.09 (7220% above median its 10-year median of 1.34)
GF Value™: zł86.63 vs. price of zł30.25 (65.1% below fair value)
No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for LTS:0RKT
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKT has been successfully added to your 
